Filip Janku
Fortuna: 1 M $ al 31/07/2026
Fortuna: 1 M $ al 31/07/2026
Filip Janku is currently Chief Medical Officer at Monte Rosa Therapeutics, Inc. since 2021.
Formerly, served as Center Medical Director & Associate Professor at The University of Texas M.D.
Anderson Cancer Center from 2012 to 2021.
Education includes a doctorate from the University of Charles.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 30/06/2026 | 60.612 ( 0,07 % ) | 1 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/06/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Corporate Officer/Principal | 01/05/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
University of Charles
University of Charles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.